|
Haloperidol versus placebo – 1 trial, 40 participants [15] |
|||
| Main outcomes |
Hal'dol |
Placebo |
RR (95% CI) |
|
|
|||
| Not improved by 2 hours |
2/29 |
4/11 |
0.19 (0.04–0.9) |
| Needing another injection |
Majority in both groups |
||
| Mental state: asleep – by 2 hours |
1/29 |
0/11 |
- |
| Leaving the study early |
0/29 |
0/11 |
- |
| Adverse effects: needing antiparkinsonian medication |
6/29 |
0/11 |
- |
Huf et al. BMC Psychiatry 2002 2:11 doi:10.1186/1471-244X-2-11 |
|||